Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

A5*

DMD gene therapy approach

Prof. Wolfgang Wurst, Helmholtz Zentrum München; Prof. Christian Kupatt, MRI, Technische Universität München; Dong-Jiunn Jeffery Truong, Helmholtz Zentrum München

Ascenion


Challenge

Duchenne muscular dystrophy (DMD) represents the most frequent hereditary childhood myopathy, leading to progressive muscle degeneration and weakness, and to premature death due to respiratory and cardiac impairment. Genetic approaches such as antisense oligonucleotide (AON)-mediated exon skipping, aimed at reframing dystrophin transcripts, has been translated into clinical trials. However, AONs offer only temporary and limited efficacy of dystrophin expression. In contrast, genome editing strategies provide a more efficient and permanent genomic correction. Recently, intravenous application of AAV9 delivering CRISPR/Cas9 components in a beagle model of DMD (exon 50 deficiency) proved successful in restoring expression of a shortened dystrophin in various muscles, including the heart. However, functional data have not been reported yet. Consequently, there still is a further need for efficient and sustained DMD therapies.


Technology

The novel therapeutic approach is an exon skipping strategy based on a split-intein-Cas9-mediated exon 51 excision which results in expression of a shortened but functional dystrophin protein (dys_delta_51-52). Proof of concept experiments have been performed in a proprietary porcine model of DMD lacking exon 52 resulting in an out-of-frame mutation with a premature stop codon and complete loss of dystrophin expression. It has been demonstrated that intramuscular application of an adeno-associated vector of serotype 9 (AAV9) carrying split-intein-Cas9 and a pair of guide RNAs targeting exon 51 induces expression of a shortened dystrophin (dys_delta_51-52) which is leading to a major structural and functional improvement of skeletal muscles. Substantially improved delivery of the AAV9-vector has been achieved by a coating with dendrimer-nanoparticles without influencing the myotropism of the AAVs.


Commercial Opportunity

The technology is available for in-licensing or further co-development.


Development Status

The therapeutic approach has been validated in Delta52-pigs. Systemic application of the AAV9-construct led to widespread muscular dystrophin expression, including diaphragm and heart in addition to skeletal muscles. Such animals showed an enhanced survival and reduced arrhythmogenic vulnerability.


Patent Situation

For the gene therapy approach a patent application has been filed by Helmholtz Zentrum München (PCT/EP2020/077634).


Further Reading

Moretti et al., Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med

(2020). doi.org/10.1038/s41591-019-0738-2


 

DMD gene therapy approach